{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"60.2","value":"0.0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"60.2","value":"0.0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"70.8","value":"0.0"},{"groupId":"OG003","lowerLimit":"0.0","upperLimit":"52.2","value":"0.0"},{"groupId":"OG004","lowerLimit":"0.0","upperLimit":"70.8","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"3"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with complete response (CR) or partial response (PR). For MDS, CR: bone marrow with ≤5% myeloblasts with normal maturation of all cell lines; HgB ≥11 g/dl, neutrophils ≥1.0x10\\^9/Liter (L), platelets ≥100x10\\^9/L, and no blasts in the peripheral blood. For MDS, PR: all CR criteria, but bone marrow blasts decreased by ≥50% over pretreatment but still \\>5%; cellularity and morphology not relevant. For MDS/MPN overlap syndromes, CR: bone marrow with ≤5% myeloblasts; no osteomyelofibrosis or ≤Grade 1 fibrosis; white blood cells ≤10X10\\^9 cells/L, HgB ≥11 g/dL, platelets ≥100x10\\^9/L/≤450x10\\^9/L, neutrophils ≥1.0x10\\^9/L, no blasts, neutrophil precursors reduced to ≤2%, monocytes ≤1x10\\^9/L in peripheral blood; complete resolution of medullary disease. For MDS/MPN overlap syndromes, PR: normalization of peripheral counts and hepatosplenomegaly with bone marrow blasts reduced by 50%, but remaining \\>5% of cellularity.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with myelodysplastic syndromes (MDS) or multiple myeloma (MM) who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 50 milligrams (mg) once daily (QD) administered as a monotherapy for up to 6 months.","id":"OG000","title":"Zilurgisertib 50 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 100 mg QD administered as a monotherapy for up to 6 months.","id":"OG001","title":"Zilurgisertib 100 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 200 mg QD administered as a monotherapy for up to 6 months.","id":"OG002","title":"Zilurgisertib 200 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 400 mg QD administered as a monotherapy for up to 6 months.","id":"OG003","title":"Zilurgisertib 400 mg QD"},{"description":"Participants with MDS or MM who were transfusion dependent or presented with symptomatic anemia received oral zilurgisertib 600 mg QD administered as a monotherapy for up to 6 months.","id":"OG004","title":"Zilurgisertib 600 mg QD"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set-MDS only. Participants with MDS/MPN overlap syndromes were excluded from analysis. The 95% confidence interval was calculated using exact binomial distribution.","reportingStatus":"POSTED","timeFrame":"up to 920 days","title":"Overall Response Rate (ORR) in MDS Participants","type":"SECONDARY","unitOfMeasure":"percentage of participants"}